CIAM
CGTX icon

Caitong International Asset Management’s Cognition Therapeutics CGTX Stock Holding History

Caitong International Asset Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Sell
1
-98
-99% -$114 ﹤0.01% 2468
2025
Q4 		$134 Buy
99
+54
+120% +$88 ﹤0.01% 1667
2025
Q3 		$61 Buy
+45
New +$61 ﹤0.01% 1794

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Caitong International Asset Management's CGTX Position: Q1 2026 in Review

Caitong International Asset Management reduced its Cognition Therapeutics (CGTX) stake by 99% in Q1 2026, selling an estimated $114 and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Caitong International Asset Management first reported a position in CGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $134 in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Caitong International Asset Management held 1 share of Cognition Therapeutics worth $1 as of Q1 2026.
  • Caitong International Asset Management sold 98 Cognition Therapeutics shares in Q1 2026, an estimated $114.
  • Cognition Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2468 holding.
  • Caitong International Asset Management first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Caitong International Asset Management's Cognition Therapeutics position peaked at $134 in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.